Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 21, Pages 15868-15882Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01206
Keywords
-
Categories
Funding
- Japan Agency for Medical Research and Development [21ak0101073j0905]
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology (JSPS/MEXT KAKENHI) [JP20K22711, JP18K07311, JP20K06568, JP17K08385, 21K05320, JP18H05498, JP18H05502]
- Takeda Science Foundation
- Naito Foundation
- Sumitomo Foundation
- Novartis Foundation (Japan) for the Promotion of Science
- Japan Foundation of Applied Enzymology
- Kobayashi Foundation for Cancer Research
- Foundation for Promotion of Cancer Research in Japan
- High-Quality Protein Crystal Growth Experiment on JEM, Japan Aerospace Exploration Agency (JAXA)
- Grants-in-Aid for Scientific Research [21K05320] Funding Source: KAKEN
Ask authors/readers for more resources
PROTAC, an important modality for targeted protein degradation, requires careful selection of appropriate linker, E3 ligase ligand, and target protein ligand for successful development. In silico simulation can be a useful tool for rational development of PROTACs.
Targeted protein degradation by proteolysis-targeting chimera (PROTAC) is one of the exciting modalities for drug discovery and biological discovery. It is important to select an appropriate linker, an E3 ligase ligand, and a target protein ligand in the development; however, it is necessary to synthesize a large number of PROTACs through trial and error. Herein, using a docking simulation of the ternary complex of a hematopoietic prostaglandin D synthase (H-PGDS) degrader, H-PGDS, and cereblon, we have succeeded in developing PROTAC(H-PGDS)-7 (6), which showed potent and selective degradation activity (DC50 = 17.3 pM) and potent suppression of prostaglandin D-2 production in KU812 cells. Additionally, in a Duchenne muscular dystrophy model using mdx mice with cardiac hypertrophy, compound 6 showed better inhibition of inflammatory cytokines than a potent H-PGDS inhibitor TFC-007. Thus, our results demonstrated that in silico simulation would be useful for the rational development of PROTACs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available